T Shiro

Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.

T Nakagawa, Toshihito Seki, T Shiro et al. · International Journal of Oncology · 1999 · 55 citations

Immunology, Pathology, Antagonist Ii +20

Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma.

Taketo Itoh, T Shiro, Toshihito Seki et al. · International Journal of Molecular Medicine · 2000 · 31 citations

Surgical Oncology, Immunology, Cell Death +20

Implantation treatment method of slow release anticancer doxorubicin containing hydroxyapatite (DOX-HAP) complex. A basic study of a new treatment for hepatic cancer

K Kunieda, Toshihito Seki, S Nakatani et al. · British Journal of Cancer · 1993 · 28 citations · Full text

Surgical Oncology, Hydroxyapatite, Medicine +10

Detection and determination of active metabolites of 1-(2-o-chlorobenzoyl-4-chlorophenyl)-5-glycyl-aminomethyl-3-dimethylcarbamoyl-1H-1,2,4-triazole hydrochloride dihydrate, (450191-S), in rat tissues, using a radioreceptor assay for benzodiazepines

Masafumi Fujimoto, Hashimoto Shin′ichiro, T Shiro et al. · Biochemical Pharmacology · 1984 · 21 citations

Pharmacological Study, Active Metabolites, Medicine +8

Percutaneous injection of a low-concentration alkaline solution targeting hepatocellular carcinoma.

T. Tamai, Takaomi Seki, M IMAMURA et al. · Oncology Reports · 2000 · 12 citations